802 related articles for article (PubMed ID: 27599725)
1. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.
Odutayo A; Wong CX; Hsiao AJ; Hopewell S; Altman DG; Emdin CA
BMJ; 2016 Sep; 354():i4482. PubMed ID: 27599725
[TBL] [Abstract][Full Text] [Related]
2. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies.
Emdin CA; Wong CX; Hsiao AJ; Altman DG; Peters SA; Woodward M; Odutayo AA
BMJ; 2016 Jan; 532():h7013. PubMed ID: 26786546
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Bansal N; Xie D; Sha D; Appel LJ; Deo R; Feldman HI; He J; Jamerson K; Kusek JW; Messe S; Navaneethan SD; Rahman M; Ricardo AC; Soliman EZ; Townsend R; Go AS
J Am Soc Nephrol; 2018 Dec; 29(12):2859-2869. PubMed ID: 30377231
[TBL] [Abstract][Full Text] [Related]
4. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.
Fauchier L; Villejoubert O; Clementy N; Bernard A; Pierre B; Angoulvant D; Ivanes F; Babuty D; Lip GY
Am J Med; 2016 Dec; 129(12):1278-1287. PubMed ID: 27476087
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.
Ruddox V; Sandven I; Munkhaugen J; Skattebu J; Edvardsen T; Otterstad JE
Eur J Prev Cardiol; 2017 Sep; 24(14):1555-1566. PubMed ID: 28617620
[TBL] [Abstract][Full Text] [Related]
6. Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.
Rattanawong P; Upala S; Riangwiwat T; Jaruvongvanich V; Sanguankeo A; Vutthikraivit W; Chung EH
J Interv Card Electrophysiol; 2018 Mar; 51(2):91-104. PubMed ID: 29332241
[TBL] [Abstract][Full Text] [Related]
7. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: A nationwide report.
Karayiannides S; Lundman P; Friberg L; Norhammar A
Diab Vasc Dis Res; 2018 Jan; 15(1):31-38. PubMed ID: 29052435
[TBL] [Abstract][Full Text] [Related]
8. Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event.
van Wijk I; Koudstaal PJ; Kappelle LJ; van Gijn J; Gorter JW; Algra A;
J Neurol Neurosurg Psychiatry; 2008 Aug; 79(8):895-9. PubMed ID: 18096680
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Flaker GC; Blackshear JL; McBride R; Kronmal RA; Halperin JL; Hart RG
J Am Coll Cardiol; 1992 Sep; 20(3):527-32. PubMed ID: 1512329
[TBL] [Abstract][Full Text] [Related]
10. Use of Mendelian randomization to evaluate the effect of atrial fibrillation on cardiovascular diseases and cardiac death.
Hu M; Tan J; Yang J; Gao X; Yang Y
ESC Heart Fail; 2023 Feb; 10(1):628-636. PubMed ID: 36404673
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
12. Atrial Fibrillation and Cardiovascular Outcomes in the Elderly.
O'Neal WT; Salahuddin T; Broughton ST; Soliman EZ
Pacing Clin Electrophysiol; 2016 Sep; 39(9):907-13. PubMed ID: 27333877
[TBL] [Abstract][Full Text] [Related]
13. The Cumulative Incidence of Stroke, Myocardial infarction, Heart Failure and Sudden Cardiac Death in Patients with Atrial Fibrillation.
Naser N; Kulic M; Dilic M; Dzubur A; Durak A; Pepic E; Smajic E; Kusljugic Z
Med Arch; 2017 Oct; 71(5):316-319. PubMed ID: 29284897
[TBL] [Abstract][Full Text] [Related]
14. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.
Adelborg K; Szépligeti SK; Holland-Bill L; Ehrenstein V; Horváth-Puhó E; Henderson VW; Sørensen HT
BMJ; 2018 Jan; 360():k96. PubMed ID: 29386181
[TBL] [Abstract][Full Text] [Related]
15. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
[TBL] [Abstract][Full Text] [Related]
17. Mode of death in heart failure: findings from the ATLAS trial.
Poole-Wilson PA; Uretsky BF; Thygesen K; Cleland JG; Massie BM; Rydén L;
Heart; 2003 Jan; 89(1):42-8. PubMed ID: 12482789
[TBL] [Abstract][Full Text] [Related]
18. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke.
Piccini JP; Hammill BG; Sinner MF; Hernandez AF; Walkey AJ; Benjamin EJ; Curtis LH; Heckbert SR
Eur Heart J; 2014 Jan; 35(4):250-6. PubMed ID: 24282186
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
